Drop In eGFR Research Articles

Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study

Background/Aims: In recent days, chronic kidney disease (CKD) is becoming an increasing public health problem. Identification of factors contributing to its progression is crucial for designing preventive interventions. Previous studies suggested that chronically high vasopressin is deleterious to the renal function. We evaluated plasma copeptin, a surrogate of vasopressin, as a predictor for renal function decline in a community cohort. Methods: Plasma copeptin was measured at baseline in 1,234 participants from the D.E.S.I.R. study, a prospective cohort from the French general population. All participants were followed for 9 years. Progression towards CKD during follow-up was defined as an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m² on at least one follow-up visit. We have also considered the criterion ‘Certain Drop in eGFR' proposed by the Kidney Disease Improving Global Outcomes (KDIGO) group. Results: Progression towards CKD was observed in 86 (7.0%) participants. Factors like age, female gender, plasma copeptin and use of angiotensin converting enzyme inhibitor or angiotensin 2 receptor blocker at baseline were positively associated, and eGFR inversely associated with CKD progression during follow-up. The hazard ratio per unit of log₁₀-transformed plasma copeptin was 1.65 (95% CI 1.06-2.54) and p = 0.02. Copeptin was similarly associated with CKD and this was observed when we considered the KDIGO criterion: OR 3.03 (95% CI 1.21-7.57), p = 0.02. Conclusion: The plasma copeptin level was independently and positively associated with progression towards CKD in a community-based cohort. Our results add to the available evidence for a deleterious effect of high vasopressin on renal health not only in selected groups of patients with CKD but also in the general population.

Risk factors for renal function decline in adults with normal kidney function: a 7-year cohort study

BackgroundWe aimed to examine the risk factors for renal function decline (RFD) in a community-based cohort of a rural Chinese population with normal kidney function (estimated glomerular filtration rate, eGFR...

The Urea-to-Creatinine Ratio Is Predictive of Worsening Kidney Function in Ambulatory Heart Failure Patients

BackgroundChanges in kidney function in heart failure patients convey important prognostic information. We investigated the association of the urea-to-creatinine (BUN/Cr) ratio, the fractional excretion of urea (FeUr), and the fractional excretion of sodium (FeNa) and subsequent declines in kidney function in ambulatory heart failure patients. Methods and ResultsWe prospectively enrolled adult patients with ejection fraction <40% at a multidisciplinary heart failure clinic and measured serial measurements of laboratory values from September 2008 to July 2011. The study outcome was changes in the estimated glomerular filtration rate (eGFR). In 138 patients contributing 10,350 patient-hours of follow-up, we found that participants with a decline of >25% in eGFR had higher mean BUN/Cr ratio (0.110 ± 0.043 vs 0.086 ± 0.026; P = .02) and no difference in the FeNa (1.81 vs 1.43; P = .2) or FeUr (32.3 vs 37.2; P = .9) compared with those with no change. There was an association of BUN/Cr ratio with the rate of change of eGFR (coefficient −25.67, 95% confidence interval [CI] −10.99 to −40.35; P < .0001). The BUN/Cr ratio was an independent predictor of eGFR drop >25% (odds ratio 1.19, 95% CI 1.07–1.32) and improved model discrimination (c-statistic increased from 0.624 to 0.693) and reclassification (net reclassification index 11.38% [P < .0001], integrated discrimination improvement 5.24% [P = .02]). ConclusionsThe BUN/Cr ratio is associated with worsening kidney function and adds incremental risk prediction information relative to traditional predictive measures in outpatients with heart failure at risk for worsening kidney disease.

High Serum Level of β2-Microglobulin in Late Posttransplant Period Predicts Subsequent Decline in Kidney Allograft Function: A Preliminary Study.

Background. Identification of patients at risk for kidney allograft (KAG) failure beyond the first posttransplant year is an unmet need. We aimed to determine whether serum beta-2-microglobulin (β2MG) in the late posttransplant period could predict a decline in KAG function. Methods. We assessed a value of single measurement of serum β2MG at one to seventeen years after transplantation in predicting the estimated glomerular filtration rate (eGFR) and the decline in eGFR over a period of two years in 79 recipients of KAG. Results. At baseline serum β2MG concentration was higher (P = 0.011) in patients with allograft dysfunction: 8.67 ± 2.48 µg/mL versus those with satisfactory graft function: 6.67 ± 2.13 µg/mL. Higher β2MG independently predicted the lower eGFR, the drop in eGFR by ≥25% after one and two years, and the value of negative eGFR slope. When combined with proteinuria and acute rejection, serum β2MG had excellent power in predicting certain drop in eGFR after one year (AUC = 0.910). In conjunction with posttransplant time serum β2MG had good accuracy in predicting certain eGFR drop after two years (AUC = 0.821). Conclusions. Elevated serum β2MG in the late posttransplant period is useful in identifying patients at risk for rapid loss of graft function.

Prediction of complications after partial nephrectomy by RENAL nephrometry score.

Discussing and planning the appropriate management for suspicious renal masses can be challenging. With the development of nephrometry scoring methods, we aimed to evaluate the ability of the RENAL nephrometry score to predict both the incidence of postoperative complications and the change in renal function after a partial nephrectomy. This was a retrospective study including 128 consecutive patients who underwent a partial nephrectomy (open and laparoscopic) for renal lesions in a tertiary UK referral centre. Univariate and multivariate ordinal regression models were used to identify associations between Clavien-Dindo classification and explanatory variables. The Kendall rank correlation coefficient was used to examine an association between RENAL nephrometry score and a drop in estimated glomerular filtration rate (eGFR) following surgery. An increase in the RENAL nephrometry score of one point resulted in greater odds of being in a higher Clavien-Dindo classification after controlling for RENAL suffix and type of surgical procedure (odds ratio [OR]: 1.29, 95% confidence interval [CI]: 1.04-1.64, p=0.043). Furthermore, a patient with the RENAL suffix 'p' (ie posterior location of tumour) had increased odds of developing more serious complications (OR: 2.60, 95% CI: 1.07-6.30, p=0.042). A correlation was shown between RENAL nephrometry score and postoperative drop in eGFR (Kendall's tau coefficient -0.24, p=0.004). To our knowledge, this is the first study that has shown the predictive ability of the RENAL nephrometry scoring system in a UK cohort both in terms of postoperative complications and change in renal function.

An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease.

PurposePredicting the timing and number of end-stage renal disease (ESRD) cases from a population of individuals with pre-ESRD chronic kidney disease (CKD) has not previously been reported. The objective is to predict the timing and number of cases of ESRD occurring over the lifetime of a cohort of hypothetical CKD patients in the US based on a range of baseline estimated glomerular filtration rate (eGFR) values and varying rates of eGFR decline.MethodsA three-state Markov model – functioning kidney, ESRD, and death – with an annual cycle length is used to project changes in baseline eGFR on long-term health outcomes in a hypothetical cohort of CKD patients. Using published eGFR-specific risk equations and adjusting for predictive characteristics, the probability of ESRD (eGFR <10), time to death, and incremental cost-effectiveness ratios for hypothetical treatments (costing US$10, $5, and $2/day), are projected over the cohort’s lifetime under two scenarios: an acute drop in eGFR (mimicking acute kidney injury) and a reduced hazard ratio for ESRD (mimicking an effective intervention).ResultsAmong CKD patients aged 50 years, an acute eGFR decrement from 45 mL/minute to 35 mL/minute yields decreases of 1.6 life-years, 1.5 quality-adjusted life-years (QALYs), 0.8 years until ESRD, and an increase of 183 per 1,000 progressing to ESRD. Among CKD patients aged 60 years, lowering the hazard ratio of ESRD to 0.8 yields values of 0.2, 0.2, 0.2, and 46 per 1,000, respectively. Incremental cost-effectiveness ratios are higher (ie, less favorable) for higher baseline eGFR, indicating that interventions occurring later in the course of disease are more likely to be economically attractive.ConclusionBoth acute kidney injury and slowing the rate of eGFR decline produce substantial shifts in expected numbers and timing of ESRD among CKD patients. This model is a useful tool for planning management of CKD patients.

Metabolic syndrome, but not insulin resistance, is associated with an increased risk of renal function decline

The purpose of this study was to evaluate the effect of metabolic syndrome (Mets) and insulin resistance (IR) on the risk of renal function decline (RFD) in a rural Chinese cohort. A total of 2696 subjects aged 40-71 years with normal renal function were followed-up for 7 years. RFD was defined using the Kidney Disease: Improving Global Outcome definition, i.e., a drop in estimated glomerular filtration rate (eGFR) category accompanied by a 25% or greater drop in eGFR from baseline or a sustained decline in eGFR of more than 5 mL/min/1.73 m(2)/year. During the 7-year follow-up, 9.0% of the subjects developed RFD. Subjects with Mets at baseline had an increased risk of RFD with an adjusted odds ratio (OR) of 1.77 (95%CI: 1.25-2.52), and there was a graded relationship between the numbers of Mets components and the risk for RFD. Exclusion of the subjects with hypertension (1.65; 0.99-2.75) or diabetes (1.86; 1.30-2.67) at baseline or further adjustment for IR (1.72; 1.15-2.57) did not substantially change the association between Mets and the risk of RFD. Moreover, the ORs of Mets status for RFD in the older group (≥55 years) were 2.14 (1.06-4.33) times of that in the younger group (<55 years) and 2.26 (1.07-4.78) times in hypercholesterolemia group (≥5.2 mmol/L) of that in the normal (<5.2 mmol/L) group. The baseline IR was not associated with the risk for RFD. Mets, but not IR, was associated with an increased risk for RFD. And there was a detrimental interaction of Mets with older age and hypercholesterolemia on the risk of RFD.

G377(P) Early renal transplant biopsies in children: rejection or calcineurin inhibitor toxicity?

AimsAn increase in transplant biopsy rate in the first month following renal transplantation (RT) was observed in our centre following implementation of an early steroid withdrawal (ESW) immunosuppression (IS) protocol...

Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea: the Korean genome and epidemiology study

BackgroundElevated blood pressure (BP) is a major risk factor for the progression of chronic kidney disease (CKD). However, little is known about the influence of prehypertension on CKD. In this study, we investigated the relationship between prehypertension and CKD in a middle-aged Korean population. Furthermore, we prospectively evaluated the effect of active BP control on deterioration of kidney function during the two-year follow-up.MethodsThe Korean Genome and Epidemiology Study is a community-based prospective cohort study started in 2001, with a follow-up survey conducted every two years. A total of 9509 participants aged 40–69 years were included in a baseline study. BP was classified according to the Seventh Report of the Joint National Committee on High BP (JNC-7) categories and CKD was defined as the presence of proteinuria or eGFR< 60mL/min/1.73m2. A multivariable logistic regression model was used to identify associations between BP and CKD.ResultsThe overall prevalence of CKD was 13.2%, and significantly increased with BP level. The multivariable-adjusted odds ratio of CKD was 1.59 for prehypertension and 2.27 for hypertension, compared with a normal BP. At the two-year follow-up, among the participants with prehypertension, subjects whose BP was poorly controlled had a significantly higher risk of eGFR drop (OR, 1.37; 95% CI, 1.13-1.67), as compared to controls. The prevalence of eGFR drop was 57.8% in the controlled BP group and 66.0% in the poorly-controlled BP group.ConclusionsPrehypertension, as well as hypertension, is significantly associated with CKD among middle-aged Koreans. Our results indicate that active control of the blood-pressure of prehypertensive individuals is needed to prevent deterioration of kidney function.

Recipients of Kidneys from Expanded Criteria Donors Whose eGFR Does not Drop &gt;30% Between 1-12 Months after Transplantation Have Excellent Long-Term Graft Survival

Purpose: To determine the impact of eGFR drop lower or greater than 30% during the first yr post-kidney transplantation (KTx) on long-term death censored graft survival (DCGS). Methods: We studied 471 KTx recipients of deceased donor kidneys between 1/1990 and 12/2006. 253 pts (53.7%, 82 women, 171 men, 49±12 yrs) received standard criteria donor (SCD) kidneys, and 218 pts (46.3%, 73 women, 145 men, 52±13 yrs) received ECD kidneys. Immunosuppression consisted of ATG induction, CNI and an antimetabolite. CIT was 15.4±8.4 hr. We analyzed an eGFR drop lower or greater than 30% between 1-3, 1-12 and 3-12 months in recipients of SCD and ECD kidneys, with immediate (IGF, Scr decreased ≥20% within 24 hrs post-KTx), slow (SGF, Scr decreased < 20% within 24 hrs post-KTx and no need for dialysis) or delayed graft function (DGF, need for dialysis during the first week post-KTx), on long-term DCGS in pts whose graft survived >1 yr post-KTx. 55 recipients of SCD and 34 recipients of ECD were excluded because of graft loss, death or loss to follow-up during the first yr. Results: The impact of eGFR drop on long-term DCGS is depicted in Figures 1 and 2. There was no difference in pts with SGF. eGFR (mL/min/1.73m2) at 1, 5 and 10 yrs was 71±22, 66±22 and 57±22 respectively, in recipients of SCD and 56±18, 49±23 and 41±20 respectively, in recipients of ECD (P=0.001). An eGFR drop between 1-12 months was associated with lower DCGS (HR 2.16, P=0.02).Figure: [*P=0.002 and **P=0.01 vs. ECD Drop >30%]Figure: [P<0.0001 and **P=0.0003 vs. ECD Drop >30%]Conclusion: Recipients of ECD kidneys without an eGFR drop >30% between 1-12 months post-KTx have excellent long-term DCGS, equivalent to recipients of SCD kidneys.

Recipients of Kidneys from Expanded Criteria Donors Whose eGFR Does not Drop >30% Between 1-12 Months after Transplantation Have Excellent Long-Term Graft Survival

Purpose: To determine the impact of eGFR drop lower or greater than 30% during the first yr post-kidney transplantation (KTx) on long-term death censored graft survival (DCGS). Methods: We studied 471 KTx recipients of deceased donor kidneys between 1/1990 and 12/2006. 253 pts (53.7%, 82 women, 171 men, 49±12 yrs) received standard criteria donor (SCD) kidneys, and 218 pts (46.3%, 73 women, 145 men, 52±13 yrs) received ECD kidneys. Immunosuppression consisted of ATG induction, CNI and an antimetabolite. CIT was 15.4±8.4 hr. We analyzed an eGFR drop lower or greater than 30% between 1-3, 1-12 and 3-12 months in recipients of SCD and ECD kidneys, with immediate (IGF, Scr decreased ≥20% within 24 hrs post-KTx), slow (SGF, Scr decreased < 20% within 24 hrs post-KTx and no need for dialysis) or delayed graft function (DGF, need for dialysis during the first week post-KTx), on long-term DCGS in pts whose graft survived >1 yr post-KTx. 55 recipients of SCD and 34 recipients of ECD were excluded because of graft loss, death or loss to follow-up during the first yr. Results: The impact of eGFR drop on long-term DCGS is depicted in Figures 1 and 2. There was no difference in pts with SGF. eGFR (mL/min/1.73m2) at 1, 5 and 10 yrs was 71±22, 66±22 and 57±22 respectively, in recipients of SCD and 56±18, 49±23 and 41±20 respectively, in recipients of ECD (P=0.001). An eGFR drop between 1-12 months was associated with lower DCGS (HR 2.16, P=0.02).Figure: [*P=0.002 and **P=0.01 vs. ECD Drop >30%]Figure: [*P<0.0001 and **P=0.0003 vs. ECD Drop >30%]Conclusion: Recipients of ECD kidneys without an eGFR drop >30% between 1-12 months post-KTx have excellent long-term DCGS, equivalent to recipients of SCD kidneys.

Suprarenal graft fixation in endovascular abdominal aortic aneurysm repair is associated with a decrease in renal function

Suprarenal endograft fixation is routinely used in the endovascular repair of abdominal aortic aneurysms (EVAR) to enhance proximal endograft attachment but can be associated with an adverse outcome in renal function. This prospective study assessed the effect of suprarenal fixation on serum creatinine concentration and estimated glomerular filtration rate (eGFR), calculated by the Modified Diet in Renal Disease equation, 12 months after elective EVAR. Patients undergoing elective EVAR were divided into suprarenal vs infrarenal fixation groups matched for age, sex, smoking, and aneurysm diameter. Serum creatinine and eGFR were measured at baseline, 6, and 12 months. Included were 92 patients (two women) with a mean age of 71 ± 7 years, with 46 in each group. No device-related complications were noted. Serum creatinine did not differ significantly between groups at 6 (P = .24) or 12 (P = .08) months but significantly increased in the suprarenal group at 12 months (1.08 ± 0.36 to 1.16 ± 0.36 mg/dL; P < .001) vs baseline. The eGFR (mL/min/1.73 m(2)) did not differ significantly at baseline between the suprarenal (85 ± 27) and infrarenal (80 ± 28; P = .33) groups or at 6 months (88 ± 29 vs 77 ± 24, respectively; P = .07). At 12 months, the suprarenal group had a lower eGFR (73 ± 23) than the infrarenal group (84 ± 26; P = .027). The eGFR at 12 months showed a significant decrease in the suprarenal (80 ± 28 to 73 ± 23; P < .001) but not in the infrarenal group (85 ± 27 to 84 ± 26; P = .48). The drop in eGFR differed significantly at 12 months in the infrarenal vs the suprarenal (0.82 vs -6.94; P < .001) group. No patient progressed to end-stage renal disease or disclosed a drop in eGFR > 30%. In contrast to previous studies, this study suggests that suprarenal endograft fixation in elective EVAR is associated with a drop in eGFR at 12 months.

A Study of Renal Outcomes in African American Living Kidney Donors

Little is known about the long-term outcomes of African American living kidney donors (AALKDs). We undertook this study to describe renal outcomes of AALKDs several years after donation. We invited 107 AALKDs to come for follow-up health evaluation. Thirty-nine subjects (36.4%) completed evaluation at a mean of 7.1+/-1.6 (range, 3.9-10.2) years postdonation. The mean estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease equation [eGFR(MDRD)] at follow-up was 72.1+/-16.3 (range, 42-106) mL/min/1.73 m2, and 18% of subjects had an eGFR(MDRD) of 30 to 59. The mean absolute and relative decrease in eGFR(MDRD) from the time of donation to follow-up was 30.5+/-16.4 mL/min/1.73 m2 and 28.8%, respectively. Subjects whose body mass index was more than or equal to 35 kg/m2 (n=8) were found to have a greater decrement in e(MDRD) than those with body mass index less than 35 kg/m2 (40.1+/-7.3 and 28.3+/-17.1 mL/min/1.73 m2, respectively; P=0.009). Sixteen (41%) were hypertensive at follow-up, as defined as treatment with antihypertensive medications (n=8) or average blood pressure of more than or equal to 140 systolic or 90 mm Hg diastolic (n=10, of whom two were on antihypertensive medications). One subject had macroalbuminuria (>300 microg/mg creatinine), and six (15.4%) had microalbuminuria (30-300 microg/mg creatinine). AALKDs experience a substantial incidence of hypertension and a modest drop in eGFR(MDRD) postdonation, and obesity may increase the magnitude of renal decline. Further study is urgently needed to determine the long-term risks of AALKDs.

Sodium Bicarbonate versus Normal Saline for Protection against Contrast Nephropathy

Contrast-induced nephropathy (CIN) is a form of acute kidney injury and a significant source of morbidity and mortality. We defined CIN as an increase in serum creatinine (SCr) of 25% or more within 48 hours of receiving contrast. We retrospectively compared sodium bicarbonate with normal saline for prevention of CIN. One hundred and eighty-seven patients exposed to contrast during cardiac angiography, treated prophylactically either with sodium bicarbonate (n = 89) or with normal saline (n = 98), were studied. Baseline characteristics of both groups were similar in terms of age, amount of contrast, presence of diabetes mellitus, and use of furosemide and angiotensin-converting enzyme inhibitor. Patients in bicarbonate group had more severe renal disease with higher baseline SCr (1.58 ± 0.5 mg/dL vs. 1.28 ± 0.3 mg/dL, p = 0.001) and lower estimated glomerular filtration rate (eGFR, 51.06 ± 14.0 mL/min vs. 62.3±13.5 mL/min, p = 0.001) compared to the normal saline group. After the contrast exposure, there was significant drop in eGFR (6.4%) and increase in SCr (11.3%) in the normal saline group and no significant change in the bicarbonate group. Three patients (3.4%) in the bicarbonate group as opposed to 14 patients (14.3%) in the normal saline group developed CIN (p = 0.011). Two patients in the normal saline group and none in the bicarbonate group needed dialysis. There was no significant difference in serum creatinine at three-month follow-up in either group. The above findings suggest that hydration with intravenous sodium bicarbonate is more effective than normal saline in preventing contrast-induced nephropathy.